Lumendi完成战略重组以加速增长和创新-动脉网

Lumendi Completes Strategic Restructuring to Accelerate Growth and Innovation

CISION 等信源发布 2025-05-02 20:01



可切换为仅中文







Company Strengthens Corporate Structure, Expands U.S. Sales Team, and Announces New Distribution Partnership with MICRO-TECH Endoscopy for the

公司加强企业结构，扩大美国销售团队，并宣布与 MICRO-TECH 内窥镜达成新的分销合作伙伴关系。

United Kingdom

英国

and

和

Ireland

爱尔兰

ZUG,

楚格，

Switzerland

瑞士

May 2, 2025

2025年5月2日

/PRNewswire/ --

/美通社/ --

Lumendi AG

卢门迪股份公司

, a leader in advanced endoluminal technologies, today announced the completion of a strategic restructuring designed to fuel continued growth, innovation, and market expansion. As of

，一家先进的内腔技术领域的领导者，今天宣布完成了一项战略性重组，旨在推动持续增长、创新和市场扩展。截至

May 1

5月1日

, 2025, Lumendi AG will assume all operational activities previously conducted by Lumendi Ltd. and Lumendi International Ltd. Simultaneously, Lumendi LLC will become a 100% subsidiary of Lumendi AG and will continue development, manufacturing, and U.S. marketing and sales activities.

，2025年，Lumendi AG将承担之前由Lumendi Ltd.和Lumendi International Ltd.开展的所有运营活动。同时，Lumendi LLC将成为Lumendi AG的全资子公司，并继续进行开发、制造以及美国市场的营销和销售活动。

This new streamlined corporate structure strengthens Lumendi's ability to expand its global footprint, drive product innovation, and build new industry partnerships. Additionally, it provides strategic flexibility, supporting collaborations, financing initiatives, and market entry opportunities across multiple regions..

这一全新的简化公司结构加强了Lumendi扩展其全球足迹、推动产品创新和建立新的行业合作伙伴关系的能力。此外，它还提供了战略灵活性，支持跨多个地区的合作、融资计划和市场进入机会。

As part of its expansion strategy, Lumendi LLC has bolstered its U.S. commercial organization by filling key regional sales leadership and clinical support positions. These additions to the sales team mark the first phase of a broader initiative designed to meet the growing demand for Lumendi's cutting-edge platform technologies, including the DiLumen® Endoluminal Interventional Platform (EIP), especially the newly launched DiLumen EZ.

作为其扩展战略的一部分，Lumendi有限责任公司通过填补关键的区域销售领导和临床支持职位，加强了其美国商业组织。这些销售团队的新增力量标志着一个更广泛计划的第一阶段，该计划旨在满足对Lumendi尖端平台技术日益增长的需求，包括DiLumen®腔内介入平台（EIP），尤其是新推出的DiLumen EZ。

and DiLumen C1/Grasper.

和 DiLumen C1/抓取器。

'This restructuring is strategically important for Lumendi as it positions the company for the next phase of growth by enhancing our ability to continue to bring innovative minimally invasive endoscopic devices to market,' stated

“这一重组对Lumendi而言具有战略重要性，因为它通过增强我们持续将创新的微创内窥镜设备推向市场的能力，使公司为下一阶段的增长做好准备，”

Peter Johann, Ph.D., Chairman of Lumendi AG. '

彼得·约翰内斯，哲学博士，Lumendi AG公司董事长。'

It also allows for greater flexibility in establishing partnerships within the industry, ultimately enhancing sales. As always, we remain committed to providing healthcare professionals with the most advanced endoluminal solutions, and to creating new collaborations across the industry.'

它还能够在行业内建立合作伙伴关系时提供更大的灵活性，最终促进销售。我们一如既往地致力于为医疗保健专业人士提供最先进的腔内解决方案，并在行业内建立新的合作关系。

In conjunction with the restructuring, Lumendi AG also announces a new distribution partnership with MICRO-TECH Endoscopy ('MICRO-TECH'), covering the

伴随重组，Lumendi AG还宣布与 MICRO-TECH Endoscopy（“MICRO-TECH”）建立新的分销合作伙伴关系，涵盖

United Kingdom

英国

and

和

Ireland

爱尔兰

. MICRO-TECH, a successful and well-established provider of endoscopic solutions with a strong growth strategy and international market presence, offers an ideal partnership to expand Lumendi's access and support across the

MICRO-TECH是一家成功且成熟的内窥镜解决方案提供商，拥有强大的增长战略和国际市场地位，为扩大Lumendi的接入和支持提供了理想的合作伙伴关系。

United Kingdom

英国

and

和

Ireland

爱尔兰

. This collaboration significantly strengthens Lumendi's commercial reach and will support broader adoption of its endoluminal platforms in key European markets.

这一合作显著增强了Lumendi的商业影响力，并将支持其腔内平台在欧洲主要市场的更广泛采用。

About Lumendi

关于Lumendi

Lumendi AG

卢门迪股份公司

, based in Zug,

，总部位于楚格，

Switzerland

瑞士

, is dedicated to improving patient outcomes and reducing healthcare costs through the development of innovative endoscopic devices.

，致力于通过开发创新的内窥镜设备来改善患者预后并降低医疗成本。

Lumendi LLC